[221+ Pages Report] According to Facts & Factors, the global animal biotechnology market size was worth around USD 28.93 billion in 2024 and is predicted to grow to around USD 58.59 billion by 2034, with a compound annual growth rate (CAGR) of roughly 9.22% between 2025 and 2034.
Animal biotechnology uses biotechnological techniques and tools to manipulate or change animals for different uses. This comprises enhancing livestock production, improving the quality of animal products, and increasing disease resistance. It also encompasses the development of GM (genetically modified) animals for therapeutic, research, and agricultural applications.
The global animal biotechnology market is projected to grow substantially over the estimated period owing to the growing demand for animal-based products, genetic engineering improvements, and animal health enhancements. The rising demand for animal-based products like milk, meat, leather, and eggs has increased the adoption of biotechnological solutions to enhance disease resistance, livestock productivity, and reproductive efficiency.
Moreover, constant improvements in genetic engineering techniques fuel the industry's growth. These technologies enable accurate modifications to enhance different required traits.
Furthermore, biotechnological improvements are supporting the development of improved vaccines, therapeutic solutions, and diagnostics for animal illnesses. The emphasis on health management via biotechnology reduces mortality rates, improves disease prevention, and promises food safety.
However, the global market may be negatively affected by costly biotechnology research and the risk of ecological impact. Developing novel biotechnologies for animals needs significant investments in infrastructure and research.
The price of cloning, genetic modifications, and more may prevent small-scale companies and farmers from adopting these improved technologies. Also, the potential for genetically altered animals to adversely affect biodiversity and ecosystems is still a key concern.
Yet, the market will gain remarkable growth due to opportunities like improvements in gene therapy and the rising adoption of CRISPR and other technologies. Gene therapy improvements can cure animal genetic illnesses, with significant uses in veterinary care.
In addition, precision medicine can enhance animal wellness and health, resulting in longevity and productivity. Adopting CRISPR and other editing tools opens prospects for the growth of high-yielding and development of disease-resistant animals. These technologies may be used in agriculture and biomedical research to breed animals that are beneficial to humans.
As issues regarding environmental damage from conventional farming rise, biotechnology is proving its significance in creating highly sustainable agricultural farming. A few modernizations comprise the development of GM animals that need fewer resources like land, water, and feed while generating less waste.
An Israeli firm named Remilk, introduced its primary lab-cultured beta-lactoglobulin, a milk protein, created with genetically engineered yeast in 2024. This advancement removes the need for dairy agriculture and aids in decreasing the environmental damage of milk production.
Moreover, improvements in GM animals are aiding in reducing greenhouse gas emissions, a major issue in livestock production, thus fueling the animal biotechnology market. For instance, genetically modified fish can grow faster, needing fewer resources to reach the industry size.
Reproductive and cloning biotechnology improve breeding programs, improving animal genetic traits. These solutions allow mass production of animals with the required properties, like disease resistance and milk yield.
Artificial insemination and cloning of elite livestock are commonly performed in commercial agriculture. For instance, improved reproductive biotechnology enables mass production of quality cows for dairy use, enhancing milk production and overall productivity.
The manipulation of cloning practices and animal genomes raises ethical questions regarding natural biodiversity and animal welfare. These issues may result in strict regulations and public resistance. This may reduce applications and research in the domain, negatively affecting the global animal biotechnology industry.
In Australia, there is a rising sentiment against animal trials, with advocacy groups pressuring for the use of non-animal testing techniques. The development of substitute tools and ethical considerations fuels this inclination.
Biotechnology uses in animal health, such as diagnostics and vaccines, offer prospects to improve disease management and livestock productivity. Biotechnology allows the creation of vaccines that enhance animal health, protect livestock from diseases, and decrease economic losses in the agricultural field.
Also, improved diagnostic tools made from biotechnology modernization help early detection of diseases, resulting in better disease management and timely interventions in animals.
Adopting improved biotechnological technologies in animal agriculture comprises overcoming technical barriers associated with efficiency, scalability, and incorporation with the current infrastructures.
Although wearables have helped dairy farms improve efficiency and decrease labor costs, the ROI differs among farms. Factors like the cost of subscriptions and devices, and constant internet access in rural places may impact the efficacy of these technologies.
Resolving these challenges needs a multi-faceted model comprising financial investment, ethical deliberation, technological advancement, consumer education, and collaboration to support ecological growth in the animal biotechnology domain.
Report Attribute |
Details |
Market Size in 2023 |
USD 28.93 Billion |
Projected Market Size in 2032 |
USD 58.59 Billion |
CAGR Growth Rate |
9.22% CAGR |
Base Year |
2023 |
Forecast Years |
2024-2032 |
Key Market Players |
Zoetis, Elanco Animal Health, Merck Animal Health, Boehringer Ingelheim Animal Health, Genus Plc, Neogen Corporation, IDEXX Laboratories, Ceva Santé Animale, Phibro Animal Health, Vetoquinol, Alltech, Aratana Therapeutics, Aquabio, Hygieia Biologicals, Genotek Biolabs, and others. |
Key Segment |
By Product, By Animal Type, By Application, By End Use, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
The global animal biotechnology market is segmented based on product, animal type, application, end use, and region.
Based on product, the global market is divided into diagnostics tests, vaccines, drugs, reproductive and genetic, and feed additives. The vaccines segment held a notable market share in 2024 due to the growing demand for animal protein and supportive regulations. Vaccines are vital for preventing infectious illnesses, improving animal productivity, and reducing the prevalence of several diseases.
Growing worldwide demand for animal protein, mainly from livestock like pigs and poultry, is fueling the demand for effective vaccines to maintain optimal flock health.
Also, governments on a global scale are adopting strict regulations that motivate to promise public health and food safety.
Conversely, the diagnostics tests segment will hold a significant market share over the coming years since they allow early disease detection. This supports reducing the spread of diseases and infections and helps in timely interventions.
Based on application, the global animal biotechnology industry is segmented as diagnosis of animal diseases, treatment of animal diseases, preventive care of animals, product research & development, and others. The ‘preventive care of animals’ segment held a substantial share of the market in 2024 and is expected to lead over the estimated period as well.
Preventive care, like prophylactic treatments and vaccines, is vital for protecting animals from severe and infectious diseases. The rising emphasis majorly impacts this by enhancing productivity and animal health, preventing disease, and lowering antibiotic dependency. Genetic screening, vaccines, and other preventive tools are vital for ensuring animal wellness and controlling outbreaks.
However, the diagnosis of animal diseases segment will hold a considerable market share in the future, owing to improvements in biotechnology and growing demand for disease monitoring.
Based on end use, the global market is segmented as laboratories, point-of-care testing/in-house testing, veterinary hospitals & clinics, and others. The veterinary hospitals & clinics segment will lead the global market on the back of growing cases of zoonotic diseases and improvements in veterinary care. Veterinary clinics and hospitals offer exhaustive preventive, diagnostic, and therapeutic care. They are well-equipped with improved diagnostic technologies and therapeutic services to cure a broader range of animal problems.
Also, the growing cases of transmissible diseases among humans and animals have fueled the need for treatment and diagnostic services in veterinary clinics. Improvements in veterinary technology and medicine have fueled the potential of these facilities, thus appealing to a larger population.
Nonetheless, the laboratories segment will capture a notable market share due to its importance in offering accurate and detailed services like advanced imaging, genetic analysis, etc.
North America captured a significant share of the global animal biotechnology market in 2024. It will continue to lead in the future due to technological improvements, strong investment and infrastructure, and the presence of prominent companies.
North America is home to innovations, with leading companies engaged in livestock monitoring tools. This comprises wearables that identify diseases like avian influenza.
Also, major R&D investments coupled with the key presence of prominent biotech firms have positively impacted the developments in animal genetics, health management products, and stem cell research.
The region is also a hub for the most innovative and largest animal biotechnology companies like Zoetis, Merck Animal Health, and Elanco. These firms are actively investing in R&D and leading in developing novel biotechnology for disease prevention, livestock management, and genetic engineering.
Europe is the second-leading region in the global animal biotechnology industry owing to strong R&D infrastructure, animal welfare emphasis, and precision medicine's growing significance. Europe holds a sophisticated and strong R&D infrastructure, mainly in molecular biology, animal genetics, and genomics.
Animal welfare and health are major priorities in several European nations. The EU has imposed strict protocols for animal health, comprising measures to promote animal wellness and avoid diseases.
The region is also growing as a leader in precision medicine, which comprises genetic details and improved tools to offer targeted treatments. This can enhance animal health, increase livestock productivity, and reduce antibiotic usage. This majorly contributes to the growth of the global industry.
The global animal biotechnology market is led by players like:
PLF tools like data analytics and wearables are actively used to manage and monitor animal health, productivity, and behavior more effectively. This results in enhanced operational efficacy and better welfare.
Biotechnology is also actively used to improve the sustainability of animal husbandry. It emphasizes enhancing feed efficiency, developing substitutes to conventional animal products like lab-cultured meat, and decreasing greenhouse gas emissions.
The global animal biotechnology market is segmented as follows:
Copyright © 2024 - 2025, All Rights Reserved, Facts and Factors